Metropolitan Life Insurance Company (MetLife)’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-7,290
| Closed | -$72.7K | – | 1715 |
|
|
2024
Q1 | $72.7K | Sell |
7,290
-632
| -8% | -$6.3K | ﹤0.01% | 1215 |
|
|
2023
Q4 | $78.1K | Hold |
7,922
| – | – | ﹤0.01% | 1213 |
|
|
2023
Q3 | $60.6K | Buy |
7,922
+373
| +5% | +$2.85K | ﹤0.01% | 1294 |
|
|
2023
Q2 | $56.4K | Hold |
7,549
| – | – | ﹤0.01% | 1352 |
|
|
2023
Q1 | $50.4K | Sell |
7,549
-826
| -10% | -$5.51K | ﹤0.01% | 1388 |
|
|
2022
Q4 | $64.6K | Hold |
8,375
| – | – | ﹤0.01% | 1319 |
|
|
2022
Q3 | $89.1K | Hold |
8,375
| – | – | ﹤0.01% | 1077 |
|
|
2022
Q2 | $68.2K | Buy |
8,375
+686
| +9% | +$5.58K | ﹤0.01% | 1305 |
|
|
2022
Q1 | $55.1K | Sell |
7,689
-22,833
| -75% | -$163K | ﹤0.01% | 1538 |
|
|
2021
Q4 | $523K | Buy |
30,522
+22,388
| +275% | +$384K | 0.01% | 1389 |
|
|
2021
Q3 | $187K | Buy |
8,134
+1,467
| +22% | +$33.8K | ﹤0.01% | 2129 |
|
|
2021
Q2 | $243K | Buy |
+6,667
| New | +$243K | ﹤0.01% | 2005 |
|